ReviewFrontiers in immunology2026
The role of intestinal microbiota in the pathogenesis of childhood asthma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastric dysbiosis and more severe histological gastritis in symptomaticFrontiers in microbiology · 2026Article
- From gut microbiota dysbiosis to immune dysregulation: pathogenic mechanisms and emerging therapeutic perspectives in pediatric asthma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood asthma represents a multifactorial inflammatory disorder shaped by genetic predisposition, environmental exposures, and immune dysregulation. Growing evidence underscores the gut microbiota as a critical mediator linking early-life microbial colonization with long-term respiratory immune outcomes. Gut commensals influence key immunological processes-including Th1/Th2/Th17/Treg balance, dendritic cell maturation, and epithelial barrier integrity-thereby shaping host susceptibility to asthma. Moreover, microbial metabolites such as SCFAs, LPS, tryptophan derivatives, and secondary bile acids serve as potent immunoregulatory agents, capable of either promoting or attenuating airway inflammation. The gut-lung axis provides a conceptual and mechanistic framework through which intestinal microbial alterations influence pulmonary immunity. This review outlines how microbial dysbiosis disrupts immune homeostasis by affecting T cell subset differentiation, dendritic and epithelial cell function, mucosal immunity, and inflammatory signaling, offering novel insights into asthma pathogenesis and highlighting promising targets for microbiota-based prevention and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.